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1. Introduction 
Apolipoproteins A-I and A-II represent >90% of 
the protein mass of human plasma high density lipo- 
proteins(HDL) [ 121. By contrast, apoA-I and apoA-II 
constitute <l% of the protein in very low density 
lipoproteins (VLDL) [ 11. ApoA-I and apoA-II in intes- 
tinal chylomicrons could serve as precursors for apoA 
proteins in HDL [3,4]. The exact processes by which 
apoA-I or apoA-II are assembled into HDL in vivo 
have not yet been completely elucidated. Although 
the interaction of apoA-I and apoA-II with phospho- 
lipid and their lipid binding sites have been studied 
[S ,6], very little information regarding the associations 
of apoA-I and apoA-II with VLDL is available. Using 
VLDL derived from type III hyperlipoproteinemic 
patients, apoA-II were shown to react with apoE; a 
major apolipoprotein of VLDL to form a stable apoE- 
ApoA-II complex [7]. Here, we report that an in vitro 
incubation (16 h at 37°C) of apoA-I and apoA-II with 
VLDL results in significant incorporation of only 
apoA-II into VLDL. Incorporation of apoA-II was 
accompanied by marked displacement of apoE 
090%) from VLDL. Since apoC proteins were not as 
readily displaced by apoA-II, results suggest hat apoE 
may be more loosely bound to VLDL than the apoC 
proteins. 
and then dialyzed against a buffer containing 0.01 M 
Tris, 0.1 M NaCl,O.Ol M NaN3, and 0.01% EDTA 
(pH 7.4). HDL obtained by ultracentrifugation [8] 
were delipidated with diethyl ether-ethanol (3: 1 ,v/v) 
and the resultant apolipoproteins were fractionated 
on Sephadex G-l 50 (2.6 X 200 cm) in the presence 
of 4 M guanidine-HCl [2]. The purified apoA-I and 
apoA-II appeared as single bands following application 
of 100 pg samples to sodium dodecyl sulfate poly- 
acrylamide gel electrophoresis (SDS-PAGE) [9]. 
2.2. Incorporation experiment 
The initial experiment was carried out using VLDL 
isolated from type V subjects. ApoA-I (1 mg) and 
apoA-II (0.1 mg) were incubated (37”C, 16 h) with 
1 ml VLDL containing 0.6 mg VLDL apolipoproteins, 
5.7 mg triacylglycerol, and 0.79 mg cholesterol. The 
mixture was then applied, in a final volume of 25 ml, 
to a KBr density gradient: 1 ml of the mixture was 
adjusted to d = 1.3 at the bottom and a stepdensity 
gradient was constructed from the bottom of the tube 
to the top with an additional 3.5 ml of d = 1.25, 
8.5 ml of d = 1.063, and 8 ml of d = 1.006. Following 
ultracentrifugation (55 000 rev./min for 3 h at 4”C), 
the sample was fractionated from top to bottom into 
29 tubes and the density was determined by a refrac- 
tometer. 
2.3. Radioimmunoassay 
2. Materials and methods 
2 .l . Lipoprotein preparation 
VLDL were isolated from plasma pooled from 5 
normal men or from 2 male patients with type V 
hyperlipoproteinemia by the method in 171. The 
VLDL were washed by recentrifugation at d = 1.006 
Double radioimmunoassays (RIAs) were performed 
as in [lo]. To detect the maximal immunoreactivity 
of apoA-I, Tween-20 was added to a final concentra- 
tion of 0.38% [lo]. As shown in [lo], the RIAs are 
specific for apoA-I or apoA-II since they do not cross- 
react with apoC-I, apoC-II, apoC-III, apoB, or apoE 
present at lOOO-fold excess. 
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3. Results and discussion 
While apoA-II is only a minor protein constituent 
of human plasma VLDL [ 11, the presence of an 
apoA-II-apoE complex in VLDL has been reported 
[7]. The complex (M, > 65 000) appears to be stable 
in 6 M urea and 7 .S% SDS as shown in PAGE. 
This study was designed to explore in vitro interac- 
tionof apoA-I and apoA-II withVLDL during incuba- 
tion of VLDL with an excess of apoA-I and apoA-II. 
In preliminary experiments we have incubated VLDL 
with apoA-I and apoA-II, respectively, at 37’C for 
16 h and found either apoA-I or apoA-II could be 
incorporated into VLDL (not shown). As demon- 
strated by radioimmunoassay, apoA-II was incorpo- 
rated into VLDL 5 -times more efficiently than apoA-I 
at equivalent concentrations. In addition, when 
apoA-I and apoA-II were ‘co-incubated’ with VLDL 
at equivalent concentrations, only apoA-II associated 
with VLDL. In subsequent experiments VLDL 
obtained from patients with type V hyperlipoprotein- 
emia were incubated with apoA-I and apoA-II at a 
ratio of 10: 1 (w/w) at 37’C for 16 h followed byden- 
sity gradient ultracentrifugation. As shown in fig.1, 
the apoA-I and apoA-II treated VLDL migrated to 
the top of the gradient. Only apoA-II was found to be 
associated withVLDL to a significant degree as judged 
by specific,radioimmunoassays. Virtually no apoA-I 
was incorporated when the incubation media con- 
tamed apoA-I and apoA-II at a ratio of 10: 1 (w/w). 
The possibility that apoA-I incorporated into 
VLDL might dissociate during ultracentrifugation or 
following the exposure to high concentrations of KBr 
was examined by utilizing an alternate VLDL isola- 
tion technique. VLDL pre-treated with apoA-I and 
apoA-II were isolated by column chromatography 
using BioGel A-l 5m [ 111. The results were similar to 
the density-gradient ultracentrifugation..No apoA-I 
was found to be associated with VLDL in the pres- 
ence of apoA-II. 
Moreover, SDS-polyacrylamide gel electrophoretic 
patterns of apoA-I/apoA-II-treated and untreated 
VLDL (fig.2) clearly demonstrate that untreated 
VLDL contain the major apolipoproteins B, E and C, 
whereas the reisolated apoA-I/apoA-II-treated VLDL 
contain only apolipoproteins B, A-II and C (pooled 
fraction no. 1 and 2, from fig.1). The bottom of the 
gradient contains primarily apoA-I and a little apoE 
(pooled fraction no. 28 and 29, from fig.1). 
ApoA-II incorporation into VLDL obtained from 
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Fig.1. Ultracentrifugational profile of apoA-I- and apoA-II- 
treated VLDL in a KBr density gradient. (A) VLDL (0.6 mg 
protein) obtained from type V subjects were incubated with 
apoA-I (1 mg) and apoA-II (0.1 mg) at 37°C for 16 h. The 
density of each fraction was determined by a refractometer. 
Each fraction contained a 0.8 ml aliquot. (B) Radioimmuno- 
assay of apoA-I and apoA-II on each fraction. 
normal subjects was also examined. After incubating 
apoA-II (1 mg) with VLDL (0.5 mg protein) for 16 h 
at 37”C, the VLDL were reisolated by a standard 
ultracentrifugation technique [8] at d = 1.006. Frac- 
tions from d < 1.006 and d > 1.006 were electropho- 
resed on SDS-polyacrylamide gel. As shown in fig.2 
(gels 4-6), apoB and apoC remained associated with 
apoA-II in the VLDL fraction, whereas no apoE was 
detected in this fraction. The apoE released from 
VLDL was recovered together with the excess of 
apoA-II in the fraction with d > 1.006 (fig.2, gel 6). 
These results suggest hat the orientation of apoE 
within VLDL may be quite different from that of 
apoC. 
From the present study VLDL appears to be a 
better ‘acceptor’ for apoA-II than for apoA-I. The 
effect of apoA-II incorporation on the lipid-protein 
stoichiometry of VLDL is shown in table 1. Follow- 
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Fig.2. SDS-PAGE of apoA-I and apoA-II or apoA-II-treated 
VLDL: (1) VLDL (20 ng) obtained from type V subjects 
prior to incubation with apoA-I and apoA-II; (2) pooled sam- 
ple from fractions I and 2 from fig.1 ; (3) pooIed sample from 
fractions 28 and 29 from fig.1; (4) VLDL (20 pg) from nor- 
mals; (5) d < 1.006 fraction of apoA-II-treated VLDL; (6) 
d > 1.006 fraction of apoA-II-treated VLDL. 
ing incubation of normal VLDL (500 yg) with a lim- 
ited amount of apoA-II (O-400 pg) for 2 h there was 
no significant change observed in total lipids (triglyc- 
erides) or total protein of reisolated VLDL. The ratio 
of triglycerides to protein remained constant follow- 
ing apoA-II incorporation. On the other hand, signifi- 
cant loss of apoE occurred during incorporation of 
apoA-II with little or no decrease in the content of 
apoC-II and apoC-III. The finding suggests that the 
surface area of VLDL surface area available for apo- 
protein deposition is limited and that apoE associates 
loosely with the lipids of the VLDL particles. At pres- 
ent, we do not know if the displacement of apoE by 
apoA-11 is due to an apolipoprotein exchange process 
or due to the lipid-protein interaction. 
It was shown in [12] that isolated exogenous 
apoA-I can incorporate into HDL and displace apoA-I 
but not apoA-II. Therefore, these results seem to sug- 
gest that the binding affinity between apoA-II and 
HDL is higher than that of apoA-I. Kinetically, the 
apolipoprotein-lipid association is quicker for apoA-II 
than for apoA-I [ 131. These data suggest hat the 
apoA-I molecule binds to HDL more loosely than 
apoA-II, and are consistent with the observations in 
[ 14,151. Incorporation of apoA-II into canine HDL 
has been studied [ 161 and it was observed that 1 mol 
apoA-I can be displaced by 2 mol apoA-II. A similar 
result is reported using human HDL showing that 
apoA-II progressively displaces apoA-I from HDL, 
whereas the lipid composition and some physical prop- 
erties of lipids are not affected [17]. 
Table 1 
LOSS of apoE, apoC-II and apoC-III following the incorporation of apoA-II into VLDL in 2 h 
No. ApoA-II Recovery of triglyc- Recovery of total 
added erides in 1 ml of protein in 1 ml of 
(/Jg) d = 1.006 top (fig) d = 1.006 top (pg) 
1 0 1290 159 
2 25 1340 151 
3 50 1490 II2 
4 100 1600 195 
5 200 1340 164 
6 400 1650 218 
Triglyceride/ pg ApoA-II 
protein ratio incorp.a 
____- - 
8.1 0.90 
8.9 10.42 
8.7 21.35 
8.2 28.05 
8.2 30.22 
1.6 41.5 
% Loss of 
ApoEb ApoC-IIa ApoC-IIIa 
-____ 
0 0 0 
<lO <lO 0 
65 0 0 
80 0 0 
85 <lO 0 
95 0 0 
a Apoprotein levels were determined by specific radioimmunoassays. Immunoreactivity of each apoprotein was in close agreement 
with the scanning profile obtained from SDSgel electrophoresis 
b ApoE level (relative) was determined by scanning SDS-polyacrylamide gels 
Normal VLDL (500 ng) was incubated with different amounts of apoA-II at 37°C for 2 h in a total volume of 1 .O ml (pH 7.4). 
The sample volume was then adjusted to 10 ml with d = 1.006 and centrifuged for 16 h 
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The interaction of apoA-II with VLDL has not yet 
been reported. The exact mechanism by which 
apoA-II displaces apoE is not clear from this study, 
although it might be explained by its loose association 
with VLDL. For example, rat apolipoprotein E 
(30-40%) is displaced upon a single ultracentrifuga- 
tion and is found affiliated with water-soluble proteins 
of d > 1.2 1 [ 181. On the other hand, in humans with 
alcoholic hepatitis or lecithincholesterol acyltrans- 
ferase (L-CAT) deficiency, HDL is elevated and apoE 
constitutes 40% of the HDL protein mass [19,20]. In 
these patients no apoE is found incorporated with 
VLDL. However, when L-CAT-deficient plasma is incu- 
bated with L-CAT, apoE is transferred from HDL to 
VLDL [ 19,201. These studies suggest hat once apoE 
enters the circulation, it associates with nascent HDL 
and is then transferred to VLDL during the choleste- 
rol esterification process. Nevertheless, it is not clear 
why cholesterol esterification would result in a dras- 
tically dynamic change of apoprotein composition in 
lipoproteins. It appears that the molecular interaction 
of apolipoproteins with lipoproteins and lipids with 
lipoproteins may establish the lipid-apoprotein com- 
position of plasma lipoproteins. Whether or not the 
net transfer of apolipoproteins to VLDL observed in 
this study has some physiological significance remains 
unclear. It would be of interest to carry out experi- 
ments using nascent HDL particles (apoE-rich HDL) 
in the presence of isolated apoA-II to follow the fate 
of apoE in the circulation. 
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